MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive gain
-$36,975K
(11.94%↑ Y/Y)
Foreign currency
translation gain (loss)
$447K
(165.16%↑ Y/Y)
Net gain
-$37,102K
(10.00%↑ Y/Y)
Unrealized loss on
marketable debt securities
-$320K
(-315.58%↓ Y/Y)
Loss from continuing
operations, net of tax
-$36,602K
(11.22%↑ Y/Y)
Loss from
discontinued operations, net...
-$500K
Income tax benefit
(provision) on continuing...
-$120K
(-407.69%↓ Y/Y)
Interest income
$2,584K
(-31.91%↓ Y/Y)
FILSPARI
$105,152K
Tiopronin Products
$19,340K
Loss from continuing
operations before income...
-$36,722K
(10.84%↑ Y/Y)
Total other income,
net
$193K
(-87.02%↓ Y/Y)
Product
$124,492K
(9835.51%↑ Y/Y)
License
$2,707K
(-20.99%↓ Y/Y)
Interest expense
$2,300K
(-19.50%↓ Y/Y)
Other (expense)
income, net
-$91K
(-116.58%↓ Y/Y)
Operating loss
-$36,915K
(13.50%↑ Y/Y)
Total revenue
$127,199K
(55.63%↑ Y/Y)
Total operating
expenses
$164,114K
(31.92%↑ Y/Y)
Selling, general and
administrative
$80,254K
(10.18%↑ Y/Y)
Research and development
$57,094K
(21.76%↑ Y/Y)
Royalty expense
$24,816K
Cost of goods sold
$1,950K
(-58.32%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)